419 related articles for article (PubMed ID: 21377397)
1. Survey of current trends in the abuse of psychotropic substances and plants in Japan.
Kikura-Hanajiri R; Uchiyama N; Goda Y
Leg Med (Tokyo); 2011 May; 13(3):109-15. PubMed ID: 21377397
[TBL] [Abstract][Full Text] [Related]
2. [Prevalence of new designer drugs and their legal status in Japan].
Kikura-Hanajiri R; Uchiyama N; Kawamura M; Ogata J; Goda Y
Yakugaku Zasshi; 2013; 133(1):31-40. PubMed ID: 23292017
[TBL] [Abstract][Full Text] [Related]
3. Changes in the prevalence of new psychoactive substances before and after the introduction of the generic scheduling of synthetic cannabinoids in Japan.
Kikura-Hanajiri R; Kawamura NU; Goda Y
Drug Test Anal; 2014; 6(7-8):832-9. PubMed ID: 24573957
[TBL] [Abstract][Full Text] [Related]
4. [Synthetic cannabinoids--the new "legal high" drugs].
Berkovitz R; Arieli M; Marom E
Harefuah; 2011 Dec; 150(12):884-7, 937. PubMed ID: 22352277
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.
Dresen S; Ferreirós N; Pütz M; Westphal F; Zimmermann R; Auwärter V
J Mass Spectrom; 2010 Oct; 45(10):1186-94. PubMed ID: 20857386
[TBL] [Abstract][Full Text] [Related]
6. Synthetic cannabinoid and cathinone use among US soldiers.
Berry-Cabán CS; Kleinschmidt PE; Rao DS; Jenkins J
US Army Med Dep J; 2012; ():19-24. PubMed ID: 23007932
[TBL] [Abstract][Full Text] [Related]
7. [Analytical data of designated substances (Shitei-Yakubutsu) controlled by the Pharmaceutical Affairs Law in Japan, part I: GC-MS and LC-MS].
Kikura-Hanajiri R; Kawamura M; Uchiyama N; Ogata J; Kamakura H; Saisho K; Goda Y
Yakugaku Zasshi; 2008 Jun; 128(6):971-9. PubMed ID: 18520144
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs of abuse.
Nelson ME; Bryant SM; Aks SE
Emerg Med Clin North Am; 2014 Feb; 32(1):1-28. PubMed ID: 24275167
[TBL] [Abstract][Full Text] [Related]
9. Review of detection frequency and type of synthetic cannabinoids in herbal compounds analyzed by Istanbul Narcotic Department of the Council of Forensic Medicine, Turkey.
Gurdal F; Asirdizer M; Aker RG; Korkut S; Gocer Y; Kucukibrahimoglu EE; Ince CH
J Forensic Leg Med; 2013 Aug; 20(6):667-72. PubMed ID: 23910858
[TBL] [Abstract][Full Text] [Related]
10. Spice drugs as a new trend: mode of action, identification and legislation.
Vardakou I; Pistos C; Spiliopoulou Ch
Toxicol Lett; 2010 Sep; 197(3):157-62. PubMed ID: 20566335
[TBL] [Abstract][Full Text] [Related]
11. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
[TBL] [Abstract][Full Text] [Related]
12. [Spice in France: mixed herbs containing synthetic cannabinoids].
Schlatter J; Chiadmi F; Chariot P
Ann Biol Clin (Paris); 2012; 70(4):413-22. PubMed ID: 22796613
[TBL] [Abstract][Full Text] [Related]
13. [Current situation and issues for analyzing illegal drug products].
Hasegawa T; Takahashi K; Saijo M; Fukiwake T; Motoki Y
Yakugaku Zasshi; 2013; 133(1):7-11. PubMed ID: 23292013
[TBL] [Abstract][Full Text] [Related]
14. [Designer drugs in Finland].
Tacke U; den Hollander B; Simojoki K; Korpi ER; Pihlainen K; Alho H
Duodecim; 2011; 127(19):2027-36. PubMed ID: 22073534
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of quasi-legal psychoactive substance use among male patients in HIV care in Japan: a cross-sectional study.
Hayashi K; Wakabayashi C; Ikushima Y; Tarui M
Subst Abuse Treat Prev Policy; 2017 Feb; 12(1):11. PubMed ID: 28231843
[TBL] [Abstract][Full Text] [Related]
16. Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products.
Uchiyama N; Matsuda S; Kawamura M; Shimokawa Y; Kikura-Hanajiri R; Aritake K; Urade Y; Goda Y
Forensic Sci Int; 2014 Oct; 243():1-13. PubMed ID: 24769262
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of newly distributed designer drugs detected in the products purchased in fiscal year 2008].
Uchiyama N; Miyazawa N; Kawamura M; Kikura-Hanajiri R; Goda Y
Yakugaku Zasshi; 2010 Feb; 130(2):263-70. PubMed ID: 20118651
[TBL] [Abstract][Full Text] [Related]
18. [Psychoactive substances in biological samples--toxicological laboratory data].
Gomółka E; Wilimowska J; Piekoszewski W; Groszek B
Przegl Lek; 2004; 61(4):323-7. PubMed ID: 15521594
[TBL] [Abstract][Full Text] [Related]
19. [Acting out and psychoactive substances: alcohol, drugs, illicit substances].
Gillet C; Polard E; Mauduit N; Allain H
Encephale; 2001; 27(4):351-9. PubMed ID: 11686057
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacological properties and dependence liabilities of synthetic cannabinoids].
Funada M
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Jun; 45(3):167-74. PubMed ID: 20681249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
